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Abstract
Sphingolipid biosynthesis is potently upregulated by factors associated with cellular stress, including numerous
chemotherapeutics, inflammatory cytokines, and glucocorticoids. Dihydroceramide desaturase 1 (Des1), the third enzyme
in the highly conserved pathway driving sphingolipid biosynthesis, introduces the 4,5-trans-double bond that typifies most
higher-order sphingolipids. Surprisingly, recent studies have shown that certain chemotherapeutics and other drugs inhibit
Des1, giving rise to a number of sphingolipids that lack the characteristic double bond. In order to assess the effect of an
altered sphingolipid profile (via Des1 inhibition) on cell function, we generated isogenic mouse embryonic fibroblasts
lacking both Des1 alleles. Lipidomic profiling revealed that these cells contained higher levels of dihydroceramide than wild-
type fibroblasts and that complex sphingolipids were comprised predominantly of the saturated backbone (e.g.
sphinganine vs. sphingosine, dihydrosphingomyelin vs. sphingomyelin, etc.). Des1 ablation activated pro-survival and
anabolic signaling intermediates (e.g. Akt/PKB, mTOR, MAPK, etc.) and provided protection from apoptosis caused by
etoposide, a chemotherapeutic that induces sphingolipid synthesis by upregulating several sphingolipid biosynthesizing
enzymes. These data reveal that the double bond present in most sphingolipids has a profound impact on cell survival
pathways, and that the manipulation of Des1 could have important effects on apoptosis.
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Introduction
Sphingolipids are comprised of a sphingosine backbone coupled
to a fatty acyl-chain. De novo sphingolipid biosynthesis involves a
highly conserved pathway initiated by the condensation of
palmitate and serine. Four sequential reactions, which occur in
the endoplasmic reticulum and possibly mitochondria [1], lead to
the formation of ceramide, the precursor for complex sphingolip-
ids such as sphingomyelin and gangliosides [2]. A number of
chemotherapeutics have been shown to induce sphingolipid
synthesis, which is the likely mechanism responsible for suppres-
sion of tumor growth [3]. In recent years, various sphingolipids
(e.g. ceramides, dihydroceramides, sphingosine, sphinganine,
ceramide 1-phoshate, sphingosine 1-phosphate, etc.) have been
implicated in the regulation of cell growth, death, and metabolism
[4,5,6,7,8].
The third reaction in the ceramide biosynthesis pathway is
catalyzed by dihydroceramide desaturase, an enzyme that
introduces a 4,5-trans-double bond into the sphinganine backbone
of dihydroceramide. Surprisingly, lipidomic analysis has recently
revealed that a number of factors including various chemother-
apeutics [9,10], reactive oxygen species [11], and resveratrol [12]
inhibit dihydroceramide desaturation, promoting accumulation of
the dihydro form of high-order sphingolipids. These observations
have prompted studies on this enzyme and this unique class of
lipids [12,13].
In the majority of tissues, the double bond is introduced by
dihydroceramide desaturase 1 (Des1). The second isoform, Des2,
is highly enriched in epithelial cells (gut, kidneys, skin), but is
largely absent from other tissues [14]. Des1 displays specificity for
synthesis of ceramide [15], while Des2 produces both ceramides
and phytoceramides [16,17]. We have previously described a
knockout mouse (Des12/2) devoid of Des1 [18] which demon-
strated a plethora of growth abnormalities and tremors, ultimately
proving lethal at about 8-weeks of age. Thus, these findings
highlight the importance of the double bond in the sphinganine
backbone in normal cellular function. However, the molecular
basis for its necessity has been enigmatic.
Previous studies that assessed the role of dihydrosphingolipids in
cellular function utilized one of three approaches. First, dihy-
droceramides were added exogenously to cultured cells
[9,14,19,20]. Second, small interfering RNAs were transfected
into cells to achieve a partial knockdown of the enzyme [13,21].
Third, the effects of the aforementioned Des1 inhibitors were
assessed [12,13]. While each of these approaches has made
significant contributions to our understanding of sphingolipid
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biology, they have inherent limitations. Incomplete or transient
inhibition of Des1 and the extreme difficulties with synthetic
dihydroceramide solubility make it difficult to study. Moreover,
many of the pharmacological inhibitors (e.g. fenretinide, resver-
atrol) are known to have multiple effectors. To gain a better
understanding of the role of Des1 and dihydrosphingolipids in
cellular stress responses, we studied cells completely devoid of
Des1. The data reveal that Des1 ablation has a potent and
dramatic effect on cell survival pathways.
Materials and Methods
MEF culture
Des1 +/+ or 2/2 MEFs were obtained from our previous
studies done in University of Utah and Duke University, USA
[18]. Briefly, mouse embryos were isolated from pregnant Des1 +/
+ (C57BL/6 mice) or Des1 2/2 mice (C57BL/6 mice lacking
full-length dihydroceramide desaturase1), and the cells were
immortalized by sequentially passing them in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum
(Hyclone, Thermo Scientific, USA) in a water jacket incubator in
the presence of 7.5% CO2 at 37uC. The studies were conducted in
accordance with the principles and procedures outlined in the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were approved by the IACUCs at the
University of Utah, and Duke University.
MTS Assay to measure cell viability
The CellTiter 96H AQueous One Solution Cell Proliferation
Assay Kit (Promega, USA) was used to measure the percentage of
viable cells after etoposide or ceramide treatment according to the
manufacturer’s protocol. 24 hours before treatment, 5000 cells/
well were placed in 96-well plates containing 100 ml of culture
medium. Cells were treated with etoposide or ceramide as
indicated in the Figure legends and 20 ml of CellTiter 96H
AQueous solution was added to each well. Following a 4-hour
incubation at 37uC in a humidified (7.5% CO2) incubator,
absorbance at 490 nm was recorded using microplate reader
(Infinite M200 PRO, TECAN, Switzerland).
Analysis of cell death
Caspase activation. The Caspase-GloH 3/7 Assay Kit
(Promega, USA) was used to quantify activation of apoptotic
caspases (caspase 3 & 7) according to the manufacturer’s protocol.
24 hours before treatment, 5000 cells were plated per well in a 96-
well plate containing 100 ml of culture medium. Cells were treated
with etoposide or ceramide as indicated in the figure legend, and
100 ml of Caspase-Glo H 3/7 assay solution was added. Following
4-hour incubation at 37uC in a humidified (7.5% CO2) incubator,
fluorescence was recorded using microplate reader (Infinite M200
PRO, TECAN, Switzerland).
Propidium iodide Staining. Cell death was measured by
staining cells with propidium iodide (PI) and detected with a
fluorescence cell sorter (Cytomics FC500, Beckman Coulter,
USA). Cells were trypsinized and were collected in 5 ml
polystyrene round-bottom tubes and then centrifuged at 300 g.
The cell pellets were washed twice with cold PBS. The pellet was
resuspended in 500 ml of PBS and 25 mg of propidium iodide was
added to stain the dead cells. To gate the total cell population
excluding cell debris, unstained cells were acquired through flow
cytometer; forward scatter (FS) and side scatter (SC) were adjusted.
Cell population was gated in the FS versus SC dot plot which
excluded polyploidy and cell debris. To detect the PI stained dead
cells, FL2 detector was used that detects red fluorescent-labeled
cells.
Protein immunoblotting
Cellular proteins were isolated by lysing cells in extraction buffer
(66 mM Tris pH 7.4, 2% SDS) in the presence of a protease
inhibitor cocktail that contains a mixture of serine, cysteine,
aspartic protease and aminopeptidase inhibitors (Cat: P8340,
SIGMA-ALDRICH, USA) and incubating on ice for 15 min
followed by brief sonication. The lysate was centrifuged at
10,000 g (4uC) for 30 minutes and the supernatant containing
soluble proteins was collected. Proteins were quantified with the
BCATM Protein Assay Kit (Thermo Scientific, USA) using BSA as
a standard.
Cell lysates were denatured in loading dye (2%SDS, 10 mM
DTT, 60 mM Tris pH 8.0, 1% bromophenol blue and 15%
glycerol) before resolving by SDS-PAGE. Following electrophore-
sis the separated proteins were transferred by electroblotting
(40 V, 12 hours at 4uC) onto a PVDF or nitrocellulose membrane.
The membrane was blocked in 1X TTS (10 mM Tris & 0.15 M
NaCl, pH 7.6) and 5% non-fat milk for 1–2 hours at room
temperature. After washing with wash buffer (1X TTS, 0.2%
Tween 20 and 0.5% nonfat milk) the blot was incubated with the
indicated primary antibodies for 2 hours at room temperature or
4uC overnight. Des1 antibody has been produced in our lab,
MDM2 has been purchased from Santa Cruz Biotechnology
(USA), and rests of the antibodies have been purchased from Cell
Signaling Technology (USA). Cleaved Caspase-3 (Asp175) Anti-
body (Cell Signaling Technology, Cat# 9661) detects endogenous
levels of activated caspase-3 (17 and 19 kDa) resulting from
cleavage adjacent to Asp175 and this antibody does not recognize
full length caspase-3. Cleaved PARP (Asp214) Antibody (Cell
Signaling Technology, Cat# 9544) detects endogenous levels of
the large fragment (89 kDa) of mouse PARP1 resulting from
caspase cleavage. The antibody does not recognize full length
PARP1 or other PARP isoforms. After several washes (3 times) the
blot was incubated in secondary antibodies (anti-mouse/rabbit
IgG) and detected by either enhanced chemiluminescence
(Amersham ECL PlusTM Western Blotting Reagent, GE Health-
care Biosciences, USA) or a LI-COR ODYSSEY scanner (LI-
COR. INC. Nebraska, USA).
Extraction of RNA from Cultured cells
Cells were washed with sterile PBS before being lysed in Trizol
Reagent (Invitrogen, Life Technologies, USA). The lysate was
transferred to a centrifuge tube, 0.2 ml chloroform/1 ml Trizol
was added, and the tube was centrifuged at 10,000 g for
15 minutes at 4uC. The supernatant was transferred to a fresh
tube and the RNA was precipitated at room temperature for
10 minutes by adding 0.5 ml isopropanol/1 ml Trizol followed by
centrifugation at 10,000 g at 4uC for 10 minutes. RNA pellets
were washed once with 75% ethanol, resuspended in DEPC
treated dH2O, and treated with Rnase free Dnase. RNA was then
purified using the QIAGEN RNAeasy column and stored at
280uC.
Real Time PCR
Total RNA was reverse transcribed to 1st strand cDNA which
was used as a template for quantitative PCR to determine the
expression of several genes in MEFs. 1st strand cDNA was
synthesized using the iScriptTM Select cDNA Synthesis Kit (Cat:
170-8897. BIO-RAD, USA). 2 mg of RNA was mixed with 2 ml of
oligo(dT)20 primer mix (purified oligo(dT)20 primer in a propri-
etary enhancer solution) in 20 ml reaction volume along with 1x
Des1 Ablation Inhibits Etoposide-Induced Apoptosis
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iScript select reaction mix and 1 ml of iScript reverse transcriptase.
The reaction mixture was incubated at 37uC for 1 hour and then
75uC for 10 minutes to inactivate the reverse transcriptase. This
cDNA was used as a template for real time PCR.
Real time PCR was performed using SsoFastTM Eva GreenH
Supermix Kit (Cat: 172-5200. BIO-RAD) according to the
manufacturer’s instructions. Briefly, 1 ml of 1st strand cDNA (from
previous reaction), 500 nM of each set of primers, and 10 ml of
SsoFastTM Eva GreenH were mixed and topped up to 20 ml with
nuclease-free water. Amplification and quantification was done
using BioRad CFX or Rotor-GeneQ (QIAGEN, Germany)
thermal cycler. Primer sequences for the different genes are stated
in Table 1.
Lipidomic profiling
To quantify levels of specific lipids, cells were harvested, washed
with ice-cold PBS, resuspended in 900 ml of ice-cold chloroform:
methanol (1:2), and incubated in ice for 15 minutes with vortexing
every 5-minutes. Four hundred microliters of ice-cold dH2O and
300 ml of ice-cold chloroform were added to the samples, which
were then centrifuged at 8000 g for 2 min at 4uC. Lower organic
phase was transferred into a clean microfuge tube. The collected
samples were dried under a stream of nitrogen and stored at
280uC for LC/MS analysis as described previously [22].
JC-1 staining to measure mitochondrial membrane
potential
Cells were grown on coverslips for 16 to 18 hours and the
medium was replaced with 10 mg/ml JC-1 (dissolved in DMSO)
containing 16 Assay buffer (JC-1 Mitochondrial Membrane
Potential Detection Kit, Cell Technology Inc. USA). The cells
were placed back into the incubator (37uC, 7.5% CO2) for
10 minutes followed by washing with HBSS (2 times) to remove
unbound dye. Monomeric JC-1 was detected by excitation at
488 nm, and emission at 527 nm. Aggregated JC-1 was detected
by excitation at 543 nm and emission at 570 nm using confocal
microscopy (Carl-Zeiss, Germany). Fluorescence intensity has
been measured using LSM software ZEN 2009 (Carl Zeiss,
Germany).
Results
Des1 ablation alters the cellular sphingolipidome
Des1 is the key enzyme that introduces a critical double bond in
the fatty-acyl chain of dihydroceramide and converts it to
ceramide in the final step of de novo ceramide biosynthesis
(Fig. 1A). The absence of Des1 in the knockout fibroblasts was
confirmed by RT-PCR and Western blotting (Fig. 1B, upper and
lower panel, respectively). Moreover, microarray studies identified
Des1 as the most markedly altered gene in these two cell lines (data
not shown). To assess the effect of Des1 ablation on the
sphingolipidome, lipids were quantified by LC/MS. Des1
knockout (Des12/2) fibroblasts had close to 80% of the
sphingolipidome replaced with dihydro-sphingolipids (i.e. sphin-
golipids lacking the characteristic double bond). Thus, ceramide
was replaced with dihydroceramide (Fig. 1C), sphingomyelin with
dihydrosphingomyelin (Fig. 1D), and sphingosine with sphinga-
nine (Fig. 1E).
To prime the system by increasing the production of
sphingolipids, we treated a subset of cells with etoposide, a
chemotherapeutic agent known to activate the de novo sphingolipid
synthesis pathway [23]. As shown in Fig. 2, etoposide doubled
levels of ceramide in the wild-type (Des1+/+) cells (Fig. 2A), but
had virtually no effect on dihydroceramides (Fig. 2B). Moreover,
etoposide increased transcript levels of a number of the
biosynthesizing enzymes; including SPT1 and SPT2, certain CerS
isoforms, and Des1 (Fig. 2C).
Des1 ablation increases cell survival and protects from
etoposide-induced apoptosis
We next sought to understand the impact of replacing
ceramides with dihydroceramides on cell survival. As shown in
Fig. 3, Des1 2/2 MEFs that contain mostly unsaturated
sphingolipids were resistant to etoposide-induced cell death
(Fig. 3A). We also assessed cell death by measuring staining with
propidium iodide. Treatment of cells for 48 hours with etoposide
killed nearly 30% of the wild-type cells, but less than 10% of the
Des1 homozygous null MEFs (Fig. 3B). Thus, Des1 ablation had a
strong protective effect on cell survival. To assess whether this was
due to protection from apoptosis, we measured caspase 3 and 7
activity by luminescence. Etoposide strongly activated caspase 3
and 7, and this was blunted in the knockout cells (Fig. 3C). To test
whether the absence of ceramide or the presence of dihydrocer-
amide induced apoptosis, we added back synthetic C2-ceramide
(100 mM) to both the wild-type and knockout cells. Ceramide was
sufficient to induce cell death, as assessed by propidium iodide
staining (Fig. 3D and Fig. S1). As etoposide also induces apoptosis
by inhibiting topoisomerase II, we have measures replicating cells
using BrdU-FITC incorporation and no difference was observed
in terms of percentage of S-phase cells (Fig. S2).
The cell survival and caspase 3/7 activity assays suggested that
the knockout cells were protected from etoposide-induced
apoptosis. To further validate this effect, we tested caspase 3 and
PARP cleavage by Western blotting. We observed large amounts
of cleaved caspase-3 in wild-type cells, and this was markedly
upregulated by etoposide. By contrast, cleaved Caspase 3 was
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virtually undetectable in the knockout cells (Fig. 4). Similar
findings were observed for PARP (Fig. 4).
We additionally assessed mitochondrial membrane integrity
using JC-1 staining, which has been used as an indicator of
mitochondrial membrane potential in a variety of cell types. JC-1
accumulates into the mitochondria based on mitochondrial
membrane potential. In the event of higher mitochondrial
membrane potential, accumulation of this dye forms J-aggregates
and produces red fluorescence. Depolarization of mitochondrial
membrane is detected by accumulation of JC-1 monomers that
produce green fluorescence. In Des1 knockout cells, we observed
more J-aggregates than that in the wild type cells indicating higher
mitochondrial membrane potential in these cells (Fig. 5).
Des1 ablation activates the pro-survival kinase Akt
Studies with ceramide analogs indicate that ceramide inhibits
activation of Akt/PKB, a serine/threonine kinase implicated in
cell survival. To test whether ceramide depletion led to a
compensatory upregulation of Akt/PKB, we assessed its activation
status by Western blotting with anti-phospho-AktSer473 antibodies.
Des1 ablation markedly increased phosphorylated Akt/PKB
activity in both vehicle and etoposide-treated cells (Fig. 6A).
Probing with an antibody directed against the consensus Akt/PKB
phosphorylation site (RXRXXS) revealed that a number of
different substrates were phosphorylated in the knockout cells
(Fig. 6B). Moreover, GSK-3b, a prominent Akt/PKB substrate
that induces apoptosis, demonstrated increased phosphorylation
on an inhibitory serine 9 residue in the knockout cells (Fig. 6C).
Figure 1. Status of ceramide and dihydroceramide to confirm the acceptability of our in vitro model. A. Structure of dihydroceramide
and ceramide. B. Des 1 knock out MEFs do not express Des1 mRNA (upper panel) as well as Des1 protein (lower panel). C. Des1 deletion inhibits
ceramide formation and causes accumulation of dihydroceramide (*P,0.01, **P,0.003). D. To confirm the efficiency of Des1 ablation, downstream
metabolites of ceramide and dihydroceramide were detected. Ceramide containing Des1 +/+ cells contain sphingomyelin while the Des12/2 contain
mostly its dihydro-species, dihydrosphingomyelin (*P,0.05, # not significant). E. A similar pattern was observed for levels of sphingosine and
dihydrosphingosine (*P,0.01, **P,0.05). The data represent the average values of experiments which have been done at least in triplicates. For all
panels, paired t-test has been used for statistical analysis.
doi:10.1371/journal.pone.0044042.g001
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Consistent with the observed increased Akt activation, p27kip1,
another downstream target implicated in stress response and
apoptosis [24,25], was downregulated in the Des1 2/2 cells
(Fig. 6C).
Mdm2, another target of Akt is, normally phosphorylated at
serine 166 residue and degrades unphosphorylated p53. Paradox-
ical to the phospho-AktSer473 status, phospho-MDM2Ser166 was
much lower in the Des12/2 cells compared to the wild-type
counterparts. However, elevated phospho-MDM2Ser166 level
correlated with the total p53 level in these cells. Upon stress, such
as etoposide treatment, p53 is phosphorylated at Ser15 residue
which in turn activates its downstream targets to induce apoptosis.
In Des12/2 cells, upon etoposide treatment, phospho-p53Ser15
level remains remarkably lower. Tumor suppressor p53 is an
Figure 2. Effect of etoposide in these cell lines. A: Etoposide induces ceramide production in Des1 +/+ cells (*P,0.001, n = 3) and B:
dihydroceramide in Des1 2/2 cells (**P,0.005, n = 3). C: Expression of key enzymes involved in ceramide synthesis were investigated to confirm the
elevated levels of different sphingolipids in these cells using real-time polymerase chain reaction. SPT initiates sphingolipid biosynthesis and both
SPT1 and SPT2 subunits are required for this process. SPT2 mRNA level in untreated Des1+/+ and Des12/2 cells is equal however, SPT2 mRNA level is
significantly higher in Des1+/+ after treating them with etoposide than Des12/2 cells (*P,0.05, n = 3). The mRNA levels of CerS family of enzymes
(CerS1-6) that contribute to the synthesis of ceramides and dihydroceramides from sphinganine were also explored. The expression level of CerS
mRNA shows that in Des1+/+ cells, CerS 2,3,4 and 6 are relatively higher after etoposide treatment compared to the Des1 2/2 counterparts. A slight
increase of CerS2 and CerS3 mRNA has been observed in etoposide treated Des12/2 cells than untreated Des12/2 cells but the differences are not
statistically significant. Des1 mRNA level was remarkably higher in Des1 +/+ cells after treating with etoposide (*P,0.05, n = 3).
doi:10.1371/journal.pone.0044042.g002
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important mediator of apoptosis that has been implicated in
etoposide-ceramide-mediated cell death [44]. Phospho-p53Ser 15
status in Des12/2 cells suggests that p53 activation could be
affected in the absence of ceramides in these cells. (Fig. 6D).
Des1 ablation downregulates PP2A
One of the prominent ways that ceramide is thought to
modulate Akt/PKB is through PP2A, which dephosphorylates and
inactivates the enzyme Akt [26]. Ceramide is a purported activator
of PP2A [27], though intermediary proteins have also been
proposed to mediate the interaction [28]. Des1 ablation decreased
both the expression (Fig. 7A) and activity (Fig. 7B) of PP2A.
PHLPP, a phosphatase that directly dephosphorylates Akt and
promotes apoptosis [29], was downregulated in Des12/2 cells
while its expression was higher in Des1+/+ cells
(Fig. 7C).Surprisingly, we also saw regulation of PDK-1 that we
demonstrated previously was not regulated by exogenous ceramide
analogs [26]. Phosphoinositide dependent kinase-1 (PDK-1), an
upstream regulator of Akt/PKB, demonstrated increased phos-
phorylation of an activating residue, Ser241 (Fig. 7C), while the
polyphosphoinositide phosphatase PTEN, which prevents Akt/
PKB activation, was downregulated to some extent (Fig. 7C).
Figure 3. Des1 ablation protects from etoposide-induced apoptosis. A.MTS assay showing percent metabolic viability after treating Des1+/+
and Des12/2 cells with 20 mM etoposide at 24 hours and 48 hours of post-treatment. MTS assay measures metabolic viability that also indicates cell
viability. After 48 hours of etoposide treatment, significant increase in metabolic viability is observed in Des12/2 cells compared to Des1+/+ cells
(*P,0.05, n = 3). B. Percentage of dead cells (PI positive cells) measured using PI (propidium iodide) staining after treating MEFs with etoposide. At
24 hours of post-etoposide treatment, percentage of PI positive cells is higher in Des1 +/+ cells compared to Des12/2 cells (# P,0.05, n = 3),
However, after 48 hours significantly high cell death is observed in Des1 +/+cells compared to Des12/2 cells (P,0.005, n = 3). C. Activation of
caspase 3 & 7 as measured by luminescence produced from luminogenic substrate of caspase 3&7. At both 24 hours and 48 hours, caspase 3/7
activation is significantly higher in Des1 +/+ cells (*P,0.05, n = 3). D. PI staining of MEFs after treatment with 20 mM etoposide, 20 mM etoposide +
100 mM C2 ceramide, and 100 mM C2 ceramide (as a control to confirm ceramide’s toxicity) for 24 hours. Addition of exogenous ceramide demise the
pro-survival property of the Des12/2 cells in presence of etoposide (#P= 0.87, n = 3, difference is not significant) when comparing between
etoposide treated Des1+/+ cells (that harbor endogenous ceramide) and Des12/2 cells treated with etoposide+exogenous ceramide (both panels
are marked with#). Additional experiments with etoposide and ceramide show the efficacy of these two compounds to induce cell death (control +/+
vs. etoposide-treated +/+ or ceramide-treated +/+ and control2/2 vs. etoposide-treated 2/2 or ceramide-treated 2/2).
doi:10.1371/journal.pone.0044042.g003
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Des1 ablation upregulates MAPK/ERK signaling
Apart from PI3-kinase/Akt, the MEK/ERK pathway also plays
a key pro-survival role by activating its downstream pathways that
are also responsible for the regulation of a number of biological
processes. Several groups have reported that PI3K plays a role in
activation of the MEK/ERK pathway [30,31]. In our study, we
also investigated the status of both phosphorylated ERK1/2
(Thr202/Tyr204) and total ERK1/2 level. After etoposide
treatment, we detected higher levels of phosphorylated ERK1/2
in Des12/2 cells whereas the total ERK1/2 level was not affected
(Fig. 8).
Discussion
Altered sphingolipid metabolism has been implicated in the
etiology of several human diseases, including type II diabetes and
Cushing’s disease [32]. Of the myriad sphingolipids, ceramide
warrants particular attention, given its increasing use as an inducer
of apoptosis in cancer treatment [33,34,35]. Several stress signals
(such as chemotherapeutic agents, ionizing radiations, inflamma-
tory cytokines, etc.) induce long-chain ceramide accumulation in
cells [36], which reduces mitochondrial mass, activates caspase-3,
and induces apoptosis [37] in a number of cell types [34,38] and
through diverse pathways (e.g., Btf, p53, etc.) [39]. However, due
to less-sensitive methods of detection, early reports were unable to
distinguish sphingolipids and dihydrosphingolipids. Thus, the
potential role for dihydroceramide, or other dihydrosphingolipids,
in processes heretofore connected with ceramide is unknown.
Apoptotic agents, such as etoposide, can induce sphingolipid
synthesis by increasing serine palmitoyltransferase (SPT) activation
[23,40]. Following treatment with etoposide, we observed similar
phenomena, namely elevated levels of ceramide and dihydrocer-
amide in Des1+/+ and Des12/2 cells, respectively. Further, after
using etoposide as an inducer of ceramide in Des1+/+ and Des12/2
cells, we have observed that dihydroceramide accumulation causes
upregulation of phospho-PDK1Ser241 and Akt/PKB, which in turn
downregulates pro-apoptotic substrates. At the same time, we
observed reduced expression of PP2A active catalytic subunit (PP2A
C) and PHLPP, both Akt/PKB inhibitors. Concomitantly, de-
creased expression of active caspase 3 was detected in Des12/2
MEFs along with anti-apoptotic phenotypes such as resistance to
etoposide and elevated phospho-AktSer 473.
Apart from inducing ceramide, etoposide also causes DNA
damage and p53 activation [41,42,43]. The precise mechanism
responsible for the down-regulation of p53 in the Des12/2MEFs
is unknown, though it likely stems from the altered ceramide/
dihydroceramide ratio and subsequent effects on pro-survival
pathways (e.g., upregulation of phospho-AktSer 473 and phospho-
Akt substrates). In support of this view, p53 might work upstream
of ceramide [44]. p53 activation induces ceramide accumulation
and p53 null cells are resistant to etoposide [45]. In vitro expression
Figure 4. Pro-apoptotic pathway is downregulated in Des1 2/2
cells. Cleaved caspase-3 and PARP cleavage are the hallmarks of
apoptosis. After 24 hours of etoposide treatment, activation of caspase-
3 and PARP cleavage was similar to untreated Des1 2/2 cells, whereas
these were markedly higher in Des1 +/+ cells. Both antibodies detect
only the cleaved forms of the proteins.
doi:10.1371/journal.pone.0044042.g004
Figure 5. Des1 ablation alters mitochondrial membrane
potential. A. JC-1 staining of Des1+/+ and Des12/2 indicates higher
mitochondrial membrane potential in Des12/2 cells. Green fluores-
cence represents monomeric JC-1 in the cytoplasm (left panel) while
red fluorescence represents J-1 aggregates accumulated in mitochon-
dria due to high mitochondrial membrane potential (middle panel).
doi:10.1371/journal.pone.0044042.g005
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of S1P lyase, the enzyme that degrades the pro-survival ceramide
metabolite S1P, can be activated by etoposide, leading to
apoptosis. This phenomenon requires p53 and p53-inducible
death domain protein (PIDD) as inhibition of p53 diminishes S1P
lyase-mediated apoptosis [46]. As stated earlier, we found that
phospho-p53Ser15 level was higher in Des1+/+ cells after treating
with etoposide, which likely contributes to the increased cell death.
However, in the absence of ceramide and its metabolites,
dihydroceramide is not sufficient to restore this function (Fig. 6D).
Sphingolipid precursors, such as ceramide, have been associated
with a wide range of human pathophysiologies, including cancer,
neurodegeneration, and cardiomyopathies in which ceramides are
described to be involved in modulating the DNA damage
response, cell cycle progression, apoptosis and autophagy. In
contrast, dihydroceramides have received less attention as in the
past, these sphingolipid species were considered biologically
inactive. In recent years, several reports demonstrate that this
sphingolipid species are not inert but are important in mediating
several cellular functions. Recent reviews by Fabrias et al. [47]
compiled the information on dihydroceramides in response to
known therapeutic agents and in the involvement of dihydro-
sphingolipids in several metabolic and signaling pathways. The
enzymatic action of dihydroceramide desaturase can be inhibited
during oxidative stress [11] and hypoxia [48] which also suggest
the involvement of dihydroceramide in these cellular events. These
data suggest that Des1 activity is a crucial marker for such cellular
events-related disorders and Des1 could be a target to manipulate
these processes. Several studies reported that the saturated fatty
acid palmitate promotes insulin resistance in the heart, adipose,
and skeletal muscle [49] whereas unsaturated fatty acids such as
oleate have protective effects against palmitate toxicity [50].
Palmitate increases Des1 level which in turn produces ceramide
and insulin resistance while oleate reduces Des1 level and prevents
palmitate induced insulin resistance. This suggests that Des1 might
play an important role in fatty acid-induced insulin resistance. Our
recent findings propose that Des1 inhibition improves insulin
sensitivity [51] and targeting this enzyme may be a possible
Figure 6. Des1 ablation results in the activation of pro-survival kinase Akt/PKB. A. Phospho-AktSer473 level is upregulated in Des12/2 cells.
B. Activated Akt phosphorylates its substrates at Ser/Thr. These phospho-Ser/Thr proteins detected by Phospho Akt Substrate (PAS) antibody shows
increased phosphorylation in Des12/2 cells. C. Among the Akt substrates, phospho-GSK-3bSer9, the inactive form of GSK-3b, is elevated in Des12/2
cells. p27Kip which is inhibited by Akt, is downregulated in Des1 2/2 cells. D. Pro-apoptotic tumor suppressor p53 is phosphorylated at Ser15
residue upon genotoxic stress such as etoposide. In Des1 2/2 cells, phospho-p53Ser15 and total p53 levels are significantly lower after treating with
etoposide. p53 upregulates its negative regulator MDM2 at the transcriptional level. MDM2 can be phosphorylated by Akt or ERK at Ser 166 residue
which in turn degrades non-phosphorylated p53. Paradoxical to the status of phospho-AktSer473, phospho-MDM2Ser166 is consistently higher in Des1
+/+ cells.
doi:10.1371/journal.pone.0044042.g006
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therapeutic means for normalizing glucose homeostasis in the
obese and diabetic.
This study raises an interesting possibility that altering the
ceramide/dihydroceramide ratio may affect cellular susceptibility
to genotoxic stress. Our data suggest that targeting de novo
ceramide synthesis may be an effective way to prevent ceramide-
mediated apoptosis. In support of this hypothesis, it has been
shown that inhibition of de novo ceramide synthesis by myriocin or
fumonisin B1 prevents cell death in the presence of excessive fatty
acid [52]. Knock down of genes that are involved in ceramide
metabolism, such as sphingosine kinase, cause a significant
increase in ceramide and induce apoptosis [53]. Critically, this
ceramide-dependent effect can be attenuated by inhibiting de novo
ceramide synthesis [53]. Collectively, our data suggest that
dihydroceramide and ceramide play opposing roles in cells,
preventing or eliciting apoptosis, respectively.
Figure 7. Akt/PKB negative regulators are downregulated in Des12/2 cells. A. The catalytic unit of PP2A, PP2AC, is downregulated in
Des12/2 cells. B. Immunoprecipitated PP2A from Des12/2 cells shows lower phophatase activity compared to that of Des1+/+ cells. C. Consistent
with this observation, Akt inhibitors PHLPP and phospho-PTENSer380 levels are lower in Des12/2 cells while the Akt activator phospho-PDK-1Ser 241 is
elevated in these cells.
doi:10.1371/journal.pone.0044042.g007
Figure 8. MAPK pathway is upregulated in Des12/2 cells.
Phospho-ERK1/2 Thr202/Tyr204 level remained high in Des12/2 cells after
treating with etoposide.
doi:10.1371/journal.pone.0044042.g008
Des1 Ablation Inhibits Etoposide-Induced Apoptosis
PLOS ONE | www.plosone.org 9 September 2012 | Volume 7 | Issue 9 | e44042
Supporting Information
Figure S1 Histogram showing PI positive cells after
treating with etoposide and/or C2 ceramide. PI staining of
MEFs after treatment with 20umM etoposide, and 20 mM
etoposide+100 mM C2 ceramide, and 100 mM C2 ceramide (as
a control to confirm ceramide’s toxicity) for 24 hours. The results
has been summarized in figure 3D. Addition of exogenous
ceramide demise the pro-survival property of the Des12/2 cells
in presence of etoposide (#P= 0.87, n = 3, difference is not
significant) when comparing between etoposide treated Des1+/+
cells (that harbor endogenous ceramide) and Des12/2 cells
treated with etoposide+exogenous ceramide (both panels are
shown in red box). Additional experiments with etoposide and
ceramide show the efficacy of these two compounds to induce cell
death (control +/+ vs. etoposide-treated +/+ or ceramide-treated
+/+ and control 2/2 vs. etoposide-treated 2/2 or ceramide-
treated 2/2).
(TIF)
Figure S2 BrdU staining to detect proliferating cells.
FITC-BrdU Flow Kits (BD PharmingenTM, USA) has been used
to measure replicating cells following manufacturer’s protocol.
Briefly, Des1+/+ and 2/2 cells were plated and grow them
overnight. Cultures were incubated with 10 mM BrdU for 1 hour
and 2 hours. Cells were trypsinized and washed twice with cold
PBS. 1.56106 cells from each experimental unit were fixed and
permeabilized in 100 ml of BD Cytofix/Cytoperm Buffer for
15 minutes at room temperature. The cells were washed once with
BD Perm Wash Buffer and incubated in 100 mL BD Cytoperm
Plus Buffer for 10 min on ice. The cells were then washed and
fixed for 5 min at room temperature followed by Dnase treatment
(300 mg/ml) for 1 hour at 37uC. This step allows exposure of
BrdU that incorporates to the DNA of the replicating cells. Cells
were then incubated with anti-BrdU-FITC antibody for 20 min-
utes at room temperature followed by staining with 7-ADD for
20 minutes at room temperature. The cells were then resuspended
in 1 ml of staining buffer and analyzed for FACS. To gate,
unstained cells were acquired through flow cytometer; forward
scatter (FS) and side scatter (SC) were adjusted that excluded
polyploidy and cell debris. To detect BrdU-FITC and 7-ADD
labeled cells, FL1 and FL3 detectors were used respectively. BrdU
incorporates to newly synthesized DNA in S-phase cells that are
detected by anti-BrdU-FITC antibody and produces green
fluorescence are shown in the box. The results in the bar diagram
are expressed as percentage of the total cells in S-phase (n = 3). No
significant difference is observed between Des1+/+ and Des12/2
cells in terms of the cells entering into S-phase (*P= 0.3, **P= 0.7).
Representative figures are shown as do plots.
(TIF)
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